nav Searchuser
Maxunitech Inc.
Beijing Multigrass Formulation Co., Ltd.

Marrone Bio Innovations’ sales up 4% in Q3 2018qrcode

Nov. 15, 2018

Favorites Print
Forward
Nov. 15, 2018
Marrone Bio Innovations, Inc. (MBII) has provided its financial results for the third quarter ended September 30, 2018.

"I am pleased to announce our strong third quarter financial results and continued operational execution throughout our business," said Dr. Pam Marrone, Founder and CEO of Marrone Bio Innovations. "I am excited about what I am seeing regarding the market's acceptance of biologicals in integrated programs with large growers. We continued to strengthen our commercial team through the addition of key hires, which when paired with customer education initiatives aimed at the integration of our brands into traditional programs while increasing our share in the organic market, we expect to drive continued growth as we move into 2019.
 
"On the financial front, we grew revenue 29% over last year to a third quarter record of $5.4 million, which is notable as the third quarter is traditionally one of our slowest times of year. In addition, our gross margins improved to a record 48.3%, while further trimming operating expenses 19% to $6.8 million. As a result of all of these factors, our cash usage from operations was the lowest in our history as a public company.
 
"On the technology front, we continue to be recognized throughout the industry for innovation. Venerate was recently named the Best New Biological Product at the prestigious Agrow Awards 2018, while we were awarded the renowned 2018 Bernard Blum Award for a Novel Biocontrol Solution by the International Biocontrol Manufacturers Association. When one considers our history of product introductions, as well as our recent EPA submission of our novel bioherbicide, MBI-014, and what we have in our pipeline for the near future, I believe we will continue to lead the integration of biologicals within the agricultural industry.
 
"We continue to see encouraging trends throughout our business, particularly in our three core areas of focus: growing revenues, increasing gross margins over the long term and diligently managing operating expenses. I believe we are well positioned to continue to execute upon our business plan, creating long-term value for our shareholders," concluded Marrone.

Picture 0/1200

More from AgroNews

Sichuan Lomon Bio Technology Co., Ltd.

Magazine

2019 Formulation & Adjuvant Technology Annual Review 2018
Chinese issue of Annual Review 2018 Chinese issue of 2018 Market Insight
2018 Market Insight Chinese issue of 2018 CRO & CRAO Manual
I wanna post a press Comment

Subscribe 

Subscribe Email: *
Name:
Mobile Number:  

Comment  

Picture 0/1200

Subscribe to daily email alerts of AgroNews.